SCHEMBL873741

SCHEMBL873741

CCNCC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28614501 0.97
SCHEMBL9741536 0.97
SCHEMBL28217455 0.97
SCHEMBL6013871 0.76
SCHEMBL562702 0.74 KDM1A (0.63)
SCHEMBL562701 0.74 KDM1A (0.63)
Diethylamine SCHEMBL27776705 0.74
SCHEMBL1018616 0.73
Diethylamine SCHEMBL29452965 0.72
SCHEMBL2009490 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119896673-A Application of GLP-1R agonist and metformin in preparation of drugs for treating diabetes and complications thereof 深圳信立泰药业股份有限公司 2025-04-29 CN claimed
CN-115305073-B Gemini surfactant for preparing water-resistant water from stratum brine and preparation method thereof 江苏海洋大学 2024-07-09 CN claimed
CN-115515938-B Salts of FXIa inhibitor compounds, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-05-10 CN claimed
EP-4351341-A1 TICK CONTROL METHODS Intervet International B.V. (NL) 2024-04-17 EP claimed
CN-117693504-A Salt of GLP-1R agonist compound, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-03-12 CN claimed
CN-111819176-B 4-azaindole compounds 百时美施贵宝公司 2023-12-15 CN claimed
WO-2022258797-A1 TICK CONTROL METHODS INTERVET INTERNATIONAL B.V. (NL) 2022-12-15 WO claimed
CN-110818712-A 1-methyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione, and synthesis method and intermediate product thereof 南京红杉生物科技有限公司 2020-02-21 CN claimed
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP claimed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO claimed
WO-2001038397-A1 N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO claimed
WO-2001038347-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO claimed
WO-2001025234-A1 QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS ADVANCED MEDICINE, INC. (US) 2001-04-12 WO claimed
EP-1078002-A1 PEPTIDE ANTIANGIOGENIC DRUGS ABBOTT LABORATORIES (US) 2001-02-28 EP claimed
WO-2000031063-A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 2000-06-02 WO claimed
WO-1999061476-A1 PEPTIDE ANTIANGIOGENIC DRUGS ABBOTT LABORATORIES (US) 1999-12-02 WO claimed
US-5807984-A CONTROLLING DISEASES; PENTAPEPTIDES BASF AKTIENEGESELLSCHAFT (DE) 1998-09-15 US claimed
EP-0859786-A1 PEPTIDE DERIVATIVES OF DOLASTATIN 15 AND THEIR USE BASF AKTIENGESELLSCHAFT (DE) 1998-08-26 EP claimed
WO-1997017364-A1 PEPTIDE DERIVATIVES OF DOLASTATIN 15 AND THEIR USE BASF AKTIENGESELLSCHAFT (DE) 1997-05-15 WO claimed
US-4067916-A TELOMERIZATION WITH A PERFLUOROETHYLENE OR PERFLUOROPROPYLENE CIBA-GEIGY AG (CH) 1978-01-10 US claimed